Gulf Pharmaceutical Industries PJSC (Julphar) announces the divestment of its subsidiary DiabTec LLC as part of a strategic focus on its core operations in diabetes care.

Information on the Target

Gulf Pharmaceutical Industries PJSC (Julphar), a leading pharmaceutical manufacturer in the Middle East and Africa, has announced the divestment of DiabTec LLC, a 100% owned subsidiary. DiabTec specializes in the production of recombinant human Insulin active pharmaceutical ingredients (API). The completion of this transaction is anticipated in the coming weeks, pending customary governmental approvals.

Despite this divestment, Julphar remains committed to the Diabetes segment, intending to bolster its Insulin portfolio. The company plans to introduce new treatment solutions for patients in the United Arab Emirates and the MENA region, with a new generation of Insulin analogues expected to launch, including a Glargine biosimilar projected for the market by 2025.

Industry Overview in the UAE

The pharmaceutical industry in the United Arab Emirates is rapidly growing, fueled by a rising demand for high-quality healthcare products and services. The government has made significant investments in healthcare infrastru